Glaukos Corporation (GKOS) Balance Sheet

The equity expansion is primarily driven by capital raises rather than organic profitability, as retained earnings have become increasingly negative, reaching -$971.3M in 2026Q2. This suggests the balance sheet is strengthening in size but not in quality, with the company relying on external funding to support its accelerating growth. Investors should monitor whether the pace of equity dilution outpaces the improvement in operating performance.

The sharp reduction in leverage appears to be a deliberate move to strengthen the balance sheet, likely through debt repayment or conversion, as total debt dropped by over $280M. This improves financial flexibility and lowers the risk of covenant breaches, but the remaining $102.8M debt still requires servicing. Given the company's persistent operating losses, the lower leverage provides a cushion, yet cash flow durability remains dependent on continued revenue growth.

The asset mix is dominated by current assets and intangibles, with PPE representing only about 20% of total assets, consistent with a medical device company that outsources manufacturing. Goodwill has been flat, suggesting no major acquisitions recently, but its presence implies potential impairment risk if growth expectations falter. The stability in PPE suggests maintenance-level capex, aligning with the low capital intensity observed in cash flow statements.

The equity base is increasingly composed of paid-in capital rather than retained earnings, which is typical for a growth-stage company but raises concerns about shareholder dilution. Stock-based compensation, which exceeded operating cash flow in 2026Q2, further dilutes ownership without a corresponding cash outflow. This suggests that reported equity growth may overstate the underlying value creation, as it is partly funded by non-cash compensation.

The current ratio, though slightly down from its peak, remains well above 5, indicating ample short-term assets to cover liabilities. Cash and equivalents of $114.5M, combined with positive operating cash flow in 2026Q2, suggest the company can fund its operations without immediate external financing. However, the cash position is modest relative to the scale of losses, and the company may need to raise additional capital if growth requires higher working capital investment.